Showing results (61-70 of 68) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Journal of Virology|April 29, 2021
Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated CytotoxicitySamuel J Resnick, Sho Iketani, Seo Jung Hong, et al.Cancer Research|July 9, 2009
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycinKer Yu, Lourdes Toral-Barza, Celine Shi, et al.Journal of Medicinal Chemistry|September 3, 2004
Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286)Arie Zask, Gary Birnberg, Katherine Cheung, et al.Journal of Medicinal Chemistry|August 4, 2009
ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidinesArie Zask, Jeroen C Verheijen, Kevin Curran, et al.Cancer Research|January 14, 2010
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2Ker Yu, Celine Shi, Lourdes Toral-Barza, et al.Journal of Medicinal Chemistry|May 30, 2003
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritisVenkatesan Aranapakam, Jamie M Davis, George T Grosu, et al.Cell|February 25, 2017
Multivalent Small-Molecule Pan-RAS InhibitorsMatthew E Welsch, Anna Kaplan, Jennifer M Chambers, et al.Nature Communications|April 8, 2022
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Hengrui Liu, Sho Iketani, Arie Zask, et al.Pageof 7